- Home
- SNCR vs COEP Comparison
SNCR vs COEP Comparison
Compare SNCR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- COEP
- Stock Information
- Founded
- SNCR 2000
- COEP 2017
- Country
- SNCR United States
- COEP United States
- Employees
- SNCR N/A
- COEP N/A
- Industry
- SNCR EDP Services
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNCR Technology
- COEP Health Care
- Exchange
- SNCR Nasdaq
- COEP Nasdaq
- Market Cap
- SNCR 70.9M
- COEP 62.4M
- IPO Year
- SNCR 2006
- COEP N/A
- Fundamental
- Price
- SNCR $6.23
- COEP $12.73
- Analyst Decision
- SNCR Strong Buy
- COEP
- Analyst Count
- SNCR 1
- COEP 0
- Target Price
- SNCR $13.00
- COEP N/A
- AVG Volume (30 Days)
- SNCR 62.9K
- COEP 39.1K
- Earning Date
- SNCR 11-11-2025
- COEP 11-12-2025
- Dividend Yield
- SNCR N/A
- COEP N/A
- EPS Growth
- SNCR N/A
- COEP N/A
- EPS
- SNCR N/A
- COEP N/A
- Revenue
- SNCR $171,870,000.00
- COEP $263,555.00
- Revenue This Year
- SNCR $1.51
- COEP N/A
- Revenue Next Year
- SNCR $5.43
- COEP N/A
- P/E Ratio
- SNCR N/A
- COEP N/A
- Revenue Growth
- SNCR 2.54
- COEP N/A
- 52 Week Low
- SNCR $5.25
- COEP $2.31
- 52 Week High
- SNCR $15.46
- COEP $14.70
- Technical
- Relative Strength Index (RSI)
- SNCR 51.19
- COEP 52.58
- Support Level
- SNCR $5.41
- COEP $12.09
- Resistance Level
- SNCR $6.27
- COEP $13.25
- Average True Range (ATR)
- SNCR 0.32
- COEP 0.67
- MACD
- SNCR 0.11
- COEP -0.11
- Stochastic Oscillator
- SNCR 86.73
- COEP 54.42
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.